Cardio Incorporated (Cardio) is a privately held health care company. It is involved in maintaining and improving the life of patients with cardiovascular disorders through translational research encompassing cellular therapy, tissue engineering and drug discovery. Over the years, the company has established and expanded Kobe TRI Laboratories in the Translational Research Informatics Center, one of the core facilities of the Kobe Medical Industry Development Project and Kobe BMA Laboratories. The company is engaged in developing regenerative medicine which is aimed to provide a solution for damaged organs with the potential of radically altering the medicine. It has entered into collaborations with universities and other companies for conducting advanced research. In September 2009, the company announced private placement for $10.2 million. Cardio is headquartered in Osaka, Japan.